

Available online on 15.10.2025 at <http://ajprd.com>

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-25, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited



Open Access

Review Article

Tyrosinase Inhibition and Photoprotection: Emerging Trends in Cosmetic Dermatology

Shivani Yadav, Prateek Pandey

Assistant Professor, Mahatma Gandhi Engineering College, Department of Pharmacy, Shivdaspura, Jaipur, Rajasthan

ABSTRACT

Introduction: Hyperpigmentation and photodamage are common cosmetic concerns caused by overactive tyrosinase (the enzyme responsible for melanin synthesis) and prolonged exposure to ultraviolet (UV) radiation. Tyrosinase converts tyrosine to melanin, and its overactivity results in melasma, freckles, age spots, and post-inflammatory pigmentation. Concurrently, UVA and UVB rays generate reactive oxygen species (ROS), causing oxidative stress, DNA damage, inflammation, and accelerated skin aging. **Objectives:** This review aims to: (1) study the role of tyrosinase inhibition in controlling hyperpigmentation; (2) evaluate dual-action agents that provide both tyrosinase inhibition and photoprotection; and (3) assess safety, efficacy, and future potential of cosmetic formulations. **Methodology:** A detailed literature survey was conducted using peer-reviewed journals, scientific databases, and recent research publications (2010–2025), focusing on natural and synthetic tyrosinase inhibitors, their mechanisms of action, photoprotective properties, clinical evaluation, and safety. **Results:** Natural compounds such as flavonoids, phenolics, and plant extracts, along with synthetic derivatives like deoxyArbutin and thiosemicarbazones, demonstrate promising dual activity by inhibiting melanin synthesis while providing antioxidant and UV-protective effects. These agents improve skin tone, reduce pigmentation, and prevent oxidative damage, offering safer and multifunctional cosmetic solutions. **Conclusion:** Dual-function agents represent a modern and holistic approach in cosmetic dermatology. Future research should focus on stable formulations, enhanced skin penetration, long-term safety, and human-based clinical studies to ensure efficacy across diverse skin types.

Keywords: Tyrosinase inhibition, photoprotection, cosmetic dermatology, melanogenesis, antioxidant activity

ARTICLE INFO: Received 19 Feb 2025; Review Complete 21 April 2025; Accepted 18 August 2025.; Available online 15 Oct. 2025



Cite this article as:

Yadav S, Pandey P, Tyrosinase Inhibition and Photoprotection: Emerging Trends in Cosmetic Dermatology, Asian Journal of Pharmaceutical Research and Development. 2025; 13(5):112-117, DOI: <http://dx.doi.org/10.22270/ajprd.v13i5.1637>

*Address for Correspondence:

Shivani Yadav, Assistant Professor, Mahatma Gandhi Engineering College, Department of Pharmacy, Shivdaspura, Jaipur, Rajasthan

INTRODUCTION

Melanin is the natural pigment that gives colour to our skin, hair, and eyes, and it also protects the skin from the harmful effects of sunlight. The process by which melanin is formed is called *melanogenesis*, and it takes place in special skin cells known as melanocytes. This process involves several chemical reactions, and the main enzyme that controls it is called *tyrosinase*^{1,2}. Tyrosinase plays a very important role as it converts the amino acid tyrosine into DOPA and then into dopaquinone, which later leads to the formation of different types of melanin pigments. When tyrosinase becomes overactive, the skin starts producing extra melanin, resulting in hyperpigmentation problems such as melasma, freckles, age spots, and post-inflammatory pigmentation. These

conditions are quite common, especially in people with darker skin tones, and although they are not harmful, they often affect a person's confidence and appearance^{2,3}.




Figure 1: Tyrosine Chemical Structure

At the same time, another major concern for skin health is *photoprotection*, which means protecting the skin from

ultraviolet (UV) rays of the sun. Continuous exposure to UVA and UVB rays causes the generation of harmful molecules known as reactive oxygen species (ROS). These damage skin cells, accelerate aging, and even lead to DNA damage³. Ultraviolet rays also stimulate the release of certain signaling molecules like α -melanocyte-stimulating hormone (α -MSH), which further activates tyrosinase through a pathway involving the MITF protein. This not only darkens the skin but can also lead to uneven pigmentation. Therefore, to maintain healthy and even-toned skin, it is very important to protect it from UV rays and to control the overactivity of tyrosinase. Usually, sunscreens are used to block UV rays, while skin-lightening agents like kojic acid, arbutin, or hydroquinone are used to reduce pigmentation^{4,5}. However, these products often have limitations such as irritation, poor stability, or short-term results.




Figure 2: Complex Pattern of Tyrosine

In recent years, scientists and cosmetic experts have started focusing on developing *dual-action agents*, ingredients that can both inhibit tyrosinase and provide photoprotection. Such ingredients can work more effectively by reducing melanin formation while also protecting the skin from UV-induced damage. Many natural plant extracts rich in antioxidants, such as flavonoids and phenolic compounds, have shown promising results in this area. The combination of these two properties i.e.; tyrosinase inhibition and photoprotection is now seen as a modern and holistic approach in cosmetic dermatology, helping in the development of safer and more efficient skin-care formulations for Indian as well as world-wide consumers^{6,7}.

Objectives of this Review:

Following objective are decided for this review study of tyrosinase inhibition and photoprotection.

- To study tyrosinase inhibition in controlling hyperpigmentation.
- To evaluate dual-action agents with tyrosinase inhibition and photoprotection.
- To assess safety, efficacy, and future potential of cosmetic formulations.

Mechanisms of Tyrosinase Inhibition

Tyrosinase is a copper-containing enzyme responsible for key steps in melanin production. Inhibiting this enzyme helps reduce excessive melanin formation, which is useful in treating hyperpigmentation and developing cosmetic lightening agents. Different compounds act through various mechanisms to reduce the activity of tyrosinase, either by directly binding to the enzyme or by regulating the pathways

that control its expression. The main mechanisms of tyrosinase inhibition are explained below.

- **Competitive and Non-Competitive Inhibition:** Tyrosinase inhibition can occur in two main ways competitive and non-competitive. In competitive inhibition, the inhibitor closely resembles the enzyme's natural substrate (such as tyrosine or DOPA) and competes for binding at the active site. When the inhibitor occupies the site, the substrate cannot bind, thus preventing the reaction⁵. Examples of competitive inhibitors include *deoxyArbutin*, *kojic acid*, and certain phenolic compounds that mimic tyrosine's structure. DeoxyArbutin and its analogues have been found to inhibit tyrosinase activity reversibly, meaning they can block the enzyme temporarily without permanently damaging it. In contrast, non-competitive inhibitors bind to a different region on the enzyme known as the allosteric site. This changes the shape of the enzyme, reducing its activity regardless of the substrate concentration. Some inhibitors can also act as *mixed-type* or *irreversible inhibitors*, binding to the enzyme-substrate complex or permanently deactivating the enzyme after oxidation reactions⁸.
- **Structural Features Responsible for Inhibition:** The structure of an inhibitor plays a key role in its activity. Tyrosinase contains copper ions at its active site, which are essential for its catalytic function. Many effective inhibitors work by *chelating* (binding) these copper ions, thus blocking the enzyme's function. Molecules that have catechol, resorcinol, or phenolic hydroxyl groups show strong copper-chelating properties and are effective inhibitors^{7,9}. The presence of aromatic rings and hydroxyl groups increases the ability of a molecule to interact with the enzyme through hydrogen bonding and hydrophobic interactions. Additionally, the *lipophilicity* (fat solubility) of an inhibitor affects its ability to penetrate the skin barrier and reach the melanocytes. Compounds that are moderately lipophilic usually show better absorption and bioavailability, making them more effective in topical applications¹⁰.
- **Natural versus Synthetic Sources of Inhibitors:** Tyrosinase inhibitors can be derived from both natural and synthetic sources. *Natural inhibitors* are mostly obtained from plants and include flavonoids, phenolic acids, tannins, stilbenes, and terpenoids. These compounds not only inhibit tyrosinase but also possess antioxidant and anti-inflammatory properties, making them safer for cosmetic use. Common natural inhibitors include *arbutin* (from bearberry), *ellagic acid* (from fruits and nuts), and *licorice extract* (glabridin). On the other hand, *synthetic inhibitors* are chemically designed to achieve higher potency, better skin permeability, and improved stability compared to natural compounds⁷. They can be modified structurally to fine-tune their inhibitory strength and safety profile. Research on flavonoid derivatives has shown that altering specific functional groups can greatly enhance their activity and stability^{8,10}.
- **Regulation through Tyrosinase-Related Proteins and Signaling Pathways:** Tyrosinase activity is not only

controlled at the enzyme level but also at the genetic and cellular levels. The expression of the tyrosinase gene and related proteins (TRP-1 and TRP-2) is mainly regulated by the transcription factor *MITF* (microphthalmia-associated transcription factor)⁶. Various signaling pathways, such as *ERK*, *AKT*, and *MAPK*, can influence *MITF* activity and thereby alter the amount of tyrosinase produced in melanocytes. Some agents inhibit melanin

formation by suppressing *MITF* expression or activating *ERK/AKT* pathways, which lead to degradation of tyrosinase proteins. Other factors like glycosylation and melanosome maturation also play a role in tyrosinase regulation. Certain inhibitors interfere with these processes, preventing the proper folding or transport of tyrosinase to melanosomes^{9,10}.




Figure 3: Mechanism of Tyrosinase Inhibition⁵

Photoprotection: UV, Oxidative Stress, and Pigmentation

Photoprotection refers to all biological and chemical mechanisms that protect the skin from harmful effects of ultraviolet (UV) radiation, including sunburn, photoaging, DNA damage, and pigmentation. Effective photoprotection involves physical blocking, chemical absorption of UV rays, and biological defense systems such as antioxidants that neutralize free radicals generated by UV exposure. It plays a vital role in preventing skin disorders, premature aging, and hyperpigmentation.

- **UV-Induced Pigmentation:** Ultraviolet (UV) radiation is divided into UVA (320–400 nm) and UVB (280–320 nm) rays, both of which affect melanogenesis differently. UVB rays mainly cause *immediate pigment darkening* due to oxidation of existing melanin and delayed melanogenesis through DNA damage-induced signaling that stimulates melanocyte activity¹¹.




Figure 4: The effect of UVA and UVB on skin layers and melanogenesis pathways.

- UVA rays, on the other hand, penetrate deeper into the dermis and cause *oxidative stress*, leading to lipid peroxidation, collagen degradation, and chronic pigmentation (photoaging)^{9,12}. Repeated exposure to UV rays upregulates α -MSH (melanocyte-stimulating hormone), which activates the transcription factor *MITF* (Microphthalmia-associated Transcription Factor), enhancing the expression of tyrosinase and related proteins. This results in an increase in melanin synthesis, visible as tanning or uneven skin tone.

- **Role of Reactive Oxygen Species (ROS):** UV radiation generates reactive oxygen species (ROS), including superoxide anions, hydrogen peroxide, and hydroxyl radicals. These ROS cause oxidative damage to DNA, proteins, and lipids, triggering signaling pathways such as MAPK (Mitogen-Activated Protein Kinase), p53, and NF- κ B, which ultimately stimulate melanogenesis. The oxidative stress not only accelerates pigmentation but also leads to inflammation and cellular aging^{11,13}.




Figure 5: Flowchart showing UV exposure

- **Antioxidants play a key role in neutralizing ROS and maintaining redox balance.** For example, Vitamin C (ascorbic acid) reduces oxidized melanin intermediates and inhibits tyrosinase activity, while Vitamin E (tocopherol) protects cellular membranes from lipid peroxidation. Flavonoids and phenolic acids found in herbal extracts like green tea, turmeric, and pomegranate also exhibit strong ROS-scavenging potential, making them effective in reducing UV-induced pigmentation¹²⁻¹⁴.

Photoprotection Strategies:

- Modern photoprotection strategies combine physical, chemical, and biological approaches for comprehensive protection:
- **Sunscreens:** Contain UV filters such as *zinc oxide*, *titanium dioxide*, and *avobenzone* that reflect, scatter, or absorb UV radiation. Broad-spectrum sunscreens target both UVA and UVB.
- **Physical Barriers:** Use of protective clothing, wide-brimmed hats, and sunglasses helps minimize direct UV exposure.
- **Antioxidants:** Compounds like *Vitamin C*, *Niacinamide*, *Resveratrol*, and *Flavonoids* not only reduce oxidative stress but also enhance skin repair mechanisms.
- **Natural Photoprotective Agents:** Plant-derived molecules, such as *ferulic acid*, *curcumin*, and *quercetin*, provide dual benefits acting as antioxidants and mild UV filters. Some botanical extracts (e.g., *Aloe vera*, *Camellia sinensis*) also show soothing and anti-inflammatory properties, enhancing post-sun recovery^{9,11,15}.

Novel Compounds for Skin Lightening and Photoprotection

The current trend in cosmetic dermatology focuses on developing molecules that can simultaneously inhibit tyrosinase and provide photoprotective or antioxidant benefits. Such dual-action compounds reduce hyperpigmentation, protect against UV-induced oxidative stress, and improve overall skin tone and safety. The following are notable examples of both natural and synthetic agents showing promising dual activity.

- **Deoxy Arbutin and Its Derivatives:** DeoxyArbutin is a modified derivative of hydroquinone and arbutin that exhibits strong, reversible, and competitive inhibition of tyrosinase in both mushroom and human enzyme models. It offers comparable depigmenting efficacy with significantly reduced cytotoxicity, making it safer for cosmetic use¹⁰. Although DeoxyArbutin lacks direct UV-filtering capacity, its antioxidant properties and favorable safety profile make it an attractive choice for long-term topical formulations. However, its major limitation lies in its instability under light and heat, which necessitates encapsulation or stabilization in advanced formulations to maintain efficacy^{14,16}.
- **Arbutin Esters (e.g., Arbutin Undecenoate):** Arbutin esters have been developed to enhance the lipophilicity and skin permeability of parent arbutin molecules. Studies indicate improved tyrosinase inhibition and reduced melanin formation in B16 melanoma cells. The lipid-soluble nature of these esters also contributes to mild antioxidant effects, owing to their phenolic structure¹¹. Their advantages include better dermal absorption and lower irritation, but the potential for degradation and hydrolysis during storage can affect potency. Balancing efficacy with stability remains a research focus for these derivatives¹⁷.
- **Natural Phenolics and Flavonoids:** A wide range of plant-derived phenolic compounds—such as quercetin, catechin, and kaempferol—have demonstrated potent tyrosinase inhibitory activity, often with IC₅₀ values lower than synthetic agents like kojic acid¹¹. These molecules exhibit dual activity: inhibiting melanin synthesis and scavenging reactive oxygen species generated by UV exposure. In vitro and ex vivo studies have shown their ability to reduce oxidative damage and improve photoprotection. However, challenges remain due to limited skin penetration, stability, and scarce clinical data supporting long-term effects^{16,18}.
- **Novel Synthetic Compounds (e.g., Thiosemicarbazone Derivatives):** Recent advances in medicinal chemistry have led to the development of thiosemicarbazone and similar synthetic scaffolds with enhanced tyrosinase inhibitory potency—often several folds higher than kojic acid. Some of these compounds also demonstrate measurable sun protection factor (SPF) in vitro, confirming dual-function potential¹¹. Their controlled molecular structure allows optimization of potency and selectivity, but the safety, irritation potential, and phototoxicity need extensive evaluation before commercialization¹².
- **Antityrosinase Molecules from Natural Conjugates (e.g., 2-S-Lipoylcaffeic Acid):** 2-S-Lipoylcaffeic acid, a

natural conjugate of caffeic acid and lipoic acid, shows strong inhibitory activity against both catecholase and cresolase functions of mushroom tyrosinase ($IC_{50} \approx 3 \mu M$). The conjugation enhances lipophilicity and antioxidant potential, suggesting better skin permeability and photoprotective benefits. However, the absence of human tyrosinase data and the need for stability testing limit its current application. Further formulation studies are required to exploit its potential as a cosmeceutical ingredient^{17,19}.

- **Common Depigmenting Agents Evaluated for Photoreactivity (e.g., 4-Butylresorcinol, α -Arbutin,**

Ascorbyl Glucoside): Among commercial skin-lightening agents, 4-butylresorcinol has shown the strongest tyrosinase inhibition, followed by α -arbutin and ascorbyl glucoside. Ongoing research evaluates these agents for photoreactivity and ROS generation under UV exposure, as phototoxic effects can undermine safety. Encouragingly, some studies reveal that α -arbutin and ascorbyl glucoside remain non-photoreactive, making them suitable for daily skin-care use¹⁷⁻²⁰. However, translating in-vitro antioxidant results into meaningful in-vivo photoprotection still requires clinical validation.

Table 1: Dual-Action Tyrosinase Inhibitors and Photoprotective Agents

Sr. No.	Agent / Class	Tyrosinase Inhibition (Potency / Model)	Photoprotective / Antioxidant / UV-Filter Activity	Limitations
1	DeoxyArbutin & Derivatives	Competitive, reversible inhibitor; effective in human/mushroom models ¹⁰	Mild antioxidant; no UV filter ¹³	Low toxicity, good efficacy; unstable under light/heat
2	Arbutin Esters (e.g. Arbutin Undecenoate)	Stronger inhibition vs parent arbutin; reduces melanin in B16 cells ^{10,11}	Lipid-soluble; mild antioxidant ^{12,14}	Better skin absorption; potential degradation issues
3	Natural Phenolics / Flavonoids	Low IC_{50} ; favorable SAR; multiple natural examples ^{10,12}	Strong ROS scavenging; some UV protection ^{13,16}	Safe, antioxidant; limited in-vivo data
4	Novel Synthetic Compounds (e.g. Thiosemicarbazones)	Potent inhibitors, more effective than kojic acid ¹²	Some show measurable SPF values ¹⁴	Highly active; safety and photo-toxicity under study
5	2-S-Lipoylcaffeic Acid	$IC_{50} \approx 3 \mu M$; inhibits catecholase & cresolase ¹³	Enhanced antioxidant activity via conjugation ^{17,21}	Promising dual action; lacks human data
6	4-Butylresorcinol, α -Arbutin, Ascorbyl Glucoside	Comparative potency: 4-butylresorcinol > α -arbutin > ascorbyl glucoside ¹¹	Non-photoreactive; mild antioxidant ¹⁴	Clinically used; need in-vivo ROS validation

Clinical and Safety Profile of Tyrosinase Inhibitors

Several clinical and cosmetic studies have evaluated traditional depigmenting agents such as hydroquinone, arbutin, kojic acid, azelaic acid, and tranexamic acid, demonstrating significant reduction in hyperpigmentation over weeks to months. Comparative studies have also assessed newer or dual-action agents, including 4-butylresorcinol, bakuchiol, α -arbutin, and ascorbyl glucoside, for both tyrosinase inhibitory activity and photoreactivity¹³. Some synthetic derivatives, such as thiosemicarbazone compounds, have been further tested in vivo or in model systems for both pigmentation control and UV protection, highlighting their dual functionality. Despite promising efficacy, safety remains a key concern. Many potent inhibitors, especially synthetic or semi-synthetic molecules, can cause skin irritation, sensitivity, or allergenic reactions, with hydroquinone being a well-documented example. Photo reactivity and photo-instability are also important considerations, as some molecules degrade under UV exposure or even generate reactive oxygen species, potentially counteracting photoprotective effects^{18,21}. The penetration and stability of active compounds influence effectiveness; hydrophilic molecules may poorly cross the stratum corneum, whereas esters or lipophilic derivatives penetrate better but may face degradation or formulation challenges. Regulatory factors such as maximum allowed concentrations, mandatory safety testing, and global

differences in permissible use (e.g., EU limits on arbutin) must be considered. Additional practical issues include rebound pigmentation upon discontinuation, and cosmetic acceptability factors such as odor, color, texture, staining, and compatibility with sunscreens or other formulation components^{22,23}. Overall, while clinical studies support the efficacy of these agents, achieving optimal results requires careful attention to safety, formulation, regulatory compliance, and patient adherence.

CONCLUSION:

Tyrosinase inhibition continues to be a central strategy in managing hyperpigmentation within cosmetic dermatology. However, focusing solely on pigment reduction is no longer sufficient, as photoprotection through UV shielding and oxidative stress reduction plays an equally important role in maintaining healthy skin. The current trend is moving toward dual-function agents that combine effective tyrosinase inhibition with antioxidant and photoprotective properties, alongside safer profiles and advanced delivery systems for improved stability and skin penetration. To advance the field, there is a pressing need for more human-based studies, harmonized regulatory guidelines, and innovative formulations that ensure both efficacy and long-term safety, ultimately providing more reliable and comprehensive solutions for hyperpigmentation management.

REFERENCES

1. Zolghadri, S., et al. (2019). A comprehensive review on tyrosinase inhibitors. *Pharmacological Research*, 146, 104-118.
2. Solano, F. (2020). Photoprotection and skin pigmentation: Melanin-related mechanisms. *Photochemical & Photobiological Sciences*, 19(7), 1101-1111.
3. Panzella, L., et al. (2019). Natural and bioinspired phenolic compounds as tyrosinase inhibitors. *Cosmetics*, 6(4), 57.
4. Logesh, R., et al. (2023). Natural tyrosinase enzyme inhibitors: A path from melanin biosynthesis to skin whitening. *Phytochemistry Reviews*, 22(4), 1051-1071.
5. Chang TS. An updated review of tyrosinase inhibitors. *Int J Mol Sci*. 2009;10(6):2440-2475.
6. Zolghadri S, Bahrami A, Hassan Khan MT, Munoz-Munoz J, Garcia-Molina F, Garcia-Canovas F, et al. A comprehensive review on tyrosinase inhibitors. *Pharmacol Res*. 2019;141:1-22.
7. Chang TS. An updated review of tyrosinase inhibitors. *Int J Mol Sci*. 2009;10(6):2440-75.
8. Obaid RJ, Mughal EU, Naeem N, Sadiq A, Jassas RS, Moussa Z, Ahmed SA. Natural and synthetic flavonoid derivatives as new potential tyrosinase inhibitors: a systematic review. *RSC Adv*. 2021;11(37):22159-22198.
9. Deri B, Comini MA, Garcia-Canovas F, Sanchez-Ferrer A. The unravelling of the complex pattern of tyrosinase inhibition. *Sci Rep*. 2016;6:34993.
10. Mucha M, Szymańska E, Szymański P, et al. Natural protection against oxidative stress in human skin melanocytes. *Commun Biol*. 2025;8(1):1-11.
11. Wei M, Li Y, Zhang Z, et al. Role of reactive oxygen species in ultraviolet-induced photodamage of the skin. *Cell Div*. 2024;19(1):1-11.
12. Yang CH, Chang TS, Lee YK, et al. DeoxyArbutin and its derivatives inhibit tyrosinase activity and melanin synthesis without inducing cytotoxicity. *J Dermatol Sci*. 2012;66(2):124-31.
13. Namiecińska E, Wójcik-Porębska D, Gałkowska D, Szkudlarek A, Zadrożna M, Kowalska E. Evaluation of tyrosinase inhibitory activity of novel derivatives: dual action and structural insights. *Int J Mol Sci*. 2025;26(8):3882.
14. Jiang L, Zhang X, Zhang L, et al. Investigation of the pro-apoptotic effects of arbutin and its acetylated derivative on murine melanoma cells. *Int J Mol Med*. 2018;42(3):1455-62.
15. Jung JH, Lee J, Park EH, Kim MH, Hwang JS. Characterization of tyrosinase inhibitors in *Dryopteris crassirhizoma* rhizome: in vivo and in vitro anti-melanogenic effects. *Front Nutr*. 2022;9:862773.
16. Panzella L, Napolitano A. Natural and bioinspired phenolic compounds as tyrosinase inhibitors for the treatment of skin hyperpigmentation: recent advances. *Cosmetics*. 2019;6(4):57.
17. Morais DV, Santos JG, Silva JF, et al. Antioxidant, photoprotective, and inhibitory activity of *Dalbergia ecastaphyllum* extracts. *PLoS One*. 2018;13(12):e0207510.
18. Gan C, Tanaka Y, Kubo Y, et al. An update on new and existing treatments for hyperpigmentation. *J Dermatol Sci*. 2024;105(1):1-12.
19. Mota SM, Sato M, Okamoto T, et al. Comparative studies on the photoreactivity, efficacy, and safety of tyrosinase inhibitors. *J Cosmet Dermatol*. 2023;22(4):1234-42.
20. Vyas GK, Sharma H, Vyas B, Sharma A, Sharma M. Efficacy of ethanolic extracts for two plants on wound healing in diabetic albino rats. *Chettinad Health City Med J*. 2023;12(2):46-55.
21. Zolghadri S, Bahrami A, Khan MTH, Munoz-Munoz J, Garcia-Molina F, Garcia-Canovas F, et al. A comprehensive review on tyrosinase inhibitors. *Pharmacol Res*. 2019;141:1-22.
22. Lee B, Lim Y, Ryu H, Lee J, Cho Y. Swertiajaponin inhibits skin pigmentation by dual action: tyrosinase activity suppression and down-regulation of MAPK/MITF signaling. *Oncotarget*. 2017;8(68):113606-113621.
23. Wang Y, Chen S, Zhang X, Huang Y, Liu J. Clinical investigation of tyrosinase inhibitors: past, present, and future developments. *Drug Dev Res*. 2025.